{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:08:50Z","timestamp":1791198530087,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Belgian Science Policy"},{"name":"Fondation M\u00e9dicale Reine Elisabeth"},{"name":"Walloon Region"},{"name":"the Fonds National de la Recherche Scientifique"},{"DOI":"10.13039\/501100001677","name":"Inserm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CNRS"},{"name":"IMPRT"},{"name":"University of Lille2"},{"name":"Lille County Hospital"},{"name":"R\u00e9gion Nord-Pas-de-Calais"},{"name":"ANR","award":["ANR JC07_184902\/ADONTAGE"],"award-info":[{"award-number":["ANR JC07_184902\/ADONTAGE"]}]},{"DOI":"10.13039\/100001671","name":"Hereditary Disease Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001671","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003134","name":"FRIA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003134","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fondation Van Buuren"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.nbd.2011.03.006","type":"journal-article","created":{"date-parts":[[2011,3,14]],"date-time":"2011-03-14T08:05:28Z","timestamp":1300089928000},"page":"524-529","source":"Crossref","is-referenced-by-count":59,"title":["Worsening of Huntington disease phenotype in CB1 receptor knockout mice"],"prefix":"10.1016","volume":"42","author":[{"given":"St\u00e9phane","family":"Mievis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ledent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2011.03.006_bb0005","first-page":"413","article-title":"Mechanisms of neuronal death in Huntington's disease. First part: general considerations and histopathological features","volume":"28","author":"Bantubungi","year":"2007","journal-title":"Rev. M\u00e9d. Brux."},{"key":"10.1016\/j.nbd.2011.03.006_bb0010","first-page":"487","article-title":"Mechanisms of neuronal death in Huntington's disease. Second part: therapeutic challenges","volume":"28","author":"Bantubungi","year":"2007","journal-title":"Rev. M\u00e9d. Brux."},{"key":"10.1016\/j.nbd.2011.03.006_bb0015","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.nbd.2004.09.017","article-title":"Minocycline in phenotypic models of Huntington's disease","volume":"18","author":"Bantubungi","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2011.03.006_bb0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease","volume":"134","author":"Bl\u00e1zquez","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2011.03.006_bb0025","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1006\/nbdi.2002.0512","article-title":"Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease","volume":"10","author":"Blum","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2011.03.006_bb0030","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1523\/JNEUROSCI.23-12-05361.2003","article-title":"A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists","volume":"23","author":"Blum","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2011.03.006_bb0035","doi-asserted-by":"crossref","first-page":"9122","DOI":"10.1523\/JNEUROSCI.22-20-09122.2002","article-title":"The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity","volume":"22","author":"Blum","year":"2002","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.nbd.2011.03.006_bb0040","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1172\/JCI27607","article-title":"Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase","volume":"116","author":"Borrell-Pag\u00e8s","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2011.03.006_bb0045","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0301-0082(99)00005-2","article-title":"Replicating Huntington's disease phenotype in experimental animals","volume":"59","author":"Brouillet","year":"1999","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2011.03.006_bb0050","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1046\/j.1471-4159.1998.70020794.x","article-title":"Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat","volume":"70","author":"Brouillet","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2011.03.006_bb0055","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1471-4159.2005.03515.x","article-title":"3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease","volume":"95","author":"Brouillet","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2011.03.006_bb0060","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1523\/JNEUROSCI.1197-04.2004","article-title":"Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease","volume":"24","author":"Canals","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2011.03.006_bb0065","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0306-4522(00)00157-3","article-title":"Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice","volume":"98","author":"Denovan-Wright","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2011.03.006_bb0070","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.neuroscience.2009.06.014","article-title":"Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease","volume":"163","author":"Dowie","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2011.03.006_bb0075","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neuroscience.2010.06.056","article-title":"Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice","volume":"170","author":"Dowie","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2011.03.006_bb0085","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.nbd.2008.01.015","article-title":"Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease","volume":"30","author":"Duan","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2011.03.006_bb0090","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.pneurobio.2006.11.003","article-title":"N-methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease","volume":"81","author":"Fan","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2011.03.006_bb0095","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1476-5381.2008.00088.x","article-title":"The endocannabinoid system as a target for the treatment of motor dysfunction","volume":"156","author":"Fernandez-Ruiz","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2011.03.006_bb0100","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2011.03.006_bb0105","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0306-4522(03)00595-5","article-title":"Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors","volume":"123","author":"Glass","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2011.03.006_bb0110","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1523\/JNEUROSCI.4232-04.2005","article-title":"Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis","volume":"25","author":"Kofalvi","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2011.03.006_bb0115","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0006-8993(01)03403-5","article-title":"Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease","volume":"929","author":"Lastres-Becker","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2011.03.006_bb0120","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00001756-200305060-00007","article-title":"Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate","volume":"14","author":"Lastres-Becker","year":"2003","journal-title":"Neuroreport"},{"key":"10.1016\/j.nbd.2011.03.006_bb0125","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1097\/00001756-200410250-00015","article-title":"Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo","volume":"15","author":"Lastres-Becker","year":"2004","journal-title":"Neuroreport"},{"key":"10.1016\/j.nbd.2011.03.006_bb0130","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.283.5400.401","article-title":"Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice","volume":"283","author":"Ledent","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.nbd.2011.03.006_bb0135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.pneurobio.2006.11.006","article-title":"The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases","volume":"81","author":"Maccarrone","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2011.03.006_bb0140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0304-3940(92)90832-R","article-title":"Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons","volume":"148","author":"Mailleux","year":"1992","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2011.03.006_bb0145","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.nbd.2008.01.014","article-title":"Tiagabine is neuroprotective in the N171-82Q and R6\/2 mouse models of Huntington's disease","volume":"30","author":"Masuda","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2011.03.006_bb0150","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.nbd.2010.09.021","article-title":"A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease","volume":"41","author":"Mievis","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2011.03.006_bb0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1385\/NMM:9:1:47","article-title":"Lack of minocycline efficiency in genetic models of Huntington's disease","volume":"9","author":"Mievis","year":"2007","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.nbd.2011.03.006_bb0160","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.neuroscience.2003.08.053","article-title":"Molecular and behavioral analysis of the R6\/1 Huntington's disease transgenic mouse","volume":"122","author":"Naver","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2011.03.006_bb0165","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1172\/JCI25303","article-title":"Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature","volume":"116","author":"Pantel","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2011.03.006_bb0170","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.neuropharm.2006.06.013","article-title":"The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum","volume":"51","author":"Pintor","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2011.03.006_bb0175","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/WCO.0b013e328304b692","article-title":"Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments","volume":"21","author":"Roze","year":"2008","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.nbd.2011.03.006_bb0180","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1460-9568.2007.05717.x","article-title":"Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors","volume":"26","author":"Sagredo","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nbd.2011.03.006_bb0185","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","article-title":"Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin","volume":"8","author":"Schilling","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2011.03.006_bb0190","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1476-5381.2010.00773.x","article-title":"Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease","volume":"160","author":"Scotter","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2011.03.006_bb0195","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00210-002-0588-0","article-title":"Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors","volume":"366","author":"Seifert","year":"2002","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"10.1016\/j.nbd.2011.03.006_bb0200","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"The Huntington's Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2011.03.006_bb0205","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1523\/JNEUROSCI.0448-07.2007","article-title":"Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum","volume":"27","author":"Uchigashima","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2011.03.006_bb0210","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2011.03.006_bb0215","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2007-971176","article-title":"Huntington's Disease","volume":"27","author":"Walker","year":"2007","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.nbd.2011.03.006_bb0225","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pneurobio.2007.01.003","article-title":"Role of brain-derived neurotrophic factor in Huntington's disease","volume":"81","author":"Zuccato","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2011.03.006_bb0230","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrneurol.2009.54","article-title":"Brain-derived neurotrophic factor in neurodegenerative diseases","volume":"5","author":"Zuccato","year":"2009","journal-title":"Nat. Rev. Neurol."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999611100088X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999611100088X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T22:17:13Z","timestamp":1588803433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096999611100088X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S096999611100088X"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2011.03.006","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}